JP2009504774A - 癌を治療するためにｓａｈａ及びターグレチンの併用方法 - Google Patents

癌を治療するためにｓａｈａ及びターグレチンの併用方法 Download PDF

Info

Publication number
JP2009504774A
JP2009504774A JP2008527161A JP2008527161A JP2009504774A JP 2009504774 A JP2009504774 A JP 2009504774A JP 2008527161 A JP2008527161 A JP 2008527161A JP 2008527161 A JP2008527161 A JP 2008527161A JP 2009504774 A JP2009504774 A JP 2009504774A
Authority
JP
Japan
Prior art keywords
day
administered
saha
dose
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008527161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504774A5 (https=
Inventor
リチヨン，ビクトリア・エム
フランケル，スタンリー・アール
アバーブツチ，ステイーブン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2009504774A publication Critical patent/JP2009504774A/ja
Publication of JP2009504774A5 publication Critical patent/JP2009504774A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008527161A 2005-08-18 2006-08-18 癌を治療するためにｓａｈａ及びターグレチンの併用方法 Withdrawn JP2009504774A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70959905P 2005-08-18 2005-08-18
US73375205P 2005-11-04 2005-11-04
PCT/US2006/032282 WO2007022408A2 (en) 2005-08-18 2006-08-18 Combination methods of saha and targretin for treating cancer

Publications (2)

Publication Number Publication Date
JP2009504774A true JP2009504774A (ja) 2009-02-05
JP2009504774A5 JP2009504774A5 (https=) 2009-09-10

Family

ID=37758430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008527161A Withdrawn JP2009504774A (ja) 2005-08-18 2006-08-18 癌を治療するためにｓａｈａ及びターグレチンの併用方法

Country Status (6)

Country Link
US (1) US20090227674A1 (https=)
EP (1) EP1933825A2 (https=)
JP (1) JP2009504774A (https=)
AU (1) AU2006279400A1 (https=)
CA (1) CA2617623A1 (https=)
WO (1) WO2007022408A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010525042A (ja) * 2007-04-25 2010-07-22 サイクラセル リミテッド 増殖性疾患を治療するためのサパシタビンの使用
JP2018532802A (ja) * 2015-10-31 2018-11-08 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせを用いた神経系障害の治療
JP2019507777A (ja) * 2016-03-10 2019-03-22 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの自己免疫疾患の治療

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101259120B (zh) 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
CN101316583A (zh) 2005-09-30 2008-12-03 生命医药公司 用特异性rxr激动剂治疗癌症
WO2013090616A1 (en) 2011-12-13 2013-06-20 Io Therapeutics, Inc. Autoimmune disorder treatment using rxr agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
WO2015084905A1 (en) * 2013-12-03 2015-06-11 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
ES2928499T3 (es) * 2014-05-21 2022-11-18 Aist Inhibición de la proliferación de células madre cancerosas
EP3280398B1 (en) * 2015-04-10 2026-02-25 Bioresponse LLC Self-emulsifying formulations of dim-related indoles
US10835507B2 (en) * 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
WO2018089861A1 (en) * 2016-11-11 2018-05-17 The Regents Of The University Of California Methods and compositions for the treatment of cancer and metabolic diseases
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
WO2020232399A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Compositions comprising hdac inhibitors and retinoids
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010525042A (ja) * 2007-04-25 2010-07-22 サイクラセル リミテッド 増殖性疾患を治療するためのサパシタビンの使用
JP2015013877A (ja) * 2007-04-25 2015-01-22 サイクラセル リミテッド 増殖性疾患を治療するためのサパシタビンの使用
JP2018532802A (ja) * 2015-10-31 2018-11-08 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせを用いた神経系障害の治療
JP2021063116A (ja) * 2015-10-31 2021-04-22 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせを用いた神経系障害の治療
JP7368859B2 (ja) 2015-10-31 2023-10-25 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせを用いた神経系障害の治療
JP2023171942A (ja) * 2015-10-31 2023-12-05 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせを用いた神経系障害の治療
JP2019507777A (ja) * 2016-03-10 2019-03-22 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの自己免疫疾患の治療
JP7169646B2 (ja) 2016-03-10 2022-11-11 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの自己免疫疾患の治療
KR20230164204A (ko) * 2016-03-10 2023-12-01 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
KR102906373B1 (ko) 2016-03-10 2025-12-30 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료

Also Published As

Publication number Publication date
EP1933825A2 (en) 2008-06-25
WO2007022408A3 (en) 2007-09-27
US20090227674A1 (en) 2009-09-10
WO2007022408A2 (en) 2007-02-22
AU2006279400A1 (en) 2007-02-22
CA2617623A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
US20070197568A1 (en) Methods of using SAHA and Erlotinib for treating cancer
JP2009504774A (ja) 癌を治療するためにｓａｈａ及びターグレチンの併用方法
JP5586896B2 (ja) 最終分化を誘導する方法
US20070197473A1 (en) Methods of using SAHA and Bortezomib for treating cancer
US20120142770A1 (en) Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
JP2007504131A (ja) 癌の組み合わせ処置法
US20100113392A1 (en) Methods of using saha and bortezomib for treating multiple myeloma
AU2006311829B8 (en) Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies
WO2007056243A2 (en) Methods of treating cancers with saha and fluorouracil and other combination therapies
HK1124783A (en) Methods of using saha and erlotinib for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090723

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090828

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090828

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091112